// App-Quantinova.ai

6577 : Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies.

Researchers

Presenter

  • Gail J. Roboz

Principal Investigators

  • Hanna Jean Khoury

  • Jamile M. Shammo

  • Mary Syto

  • Francis Burrows

  • Sara L. Zaknoen

  • Elias Jabbour

Medical Centers

  • Weill Cornell Medical College of Cornell University, New York, NY

  • Seragon Pharmaceuticals, San Diego, CA

  • Emory University, Winship Cancer Institute, Atlanta, GA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Rush University Medical Center, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Hematological malignancies

  • Hyperbilirubinemia

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Circulating tumor cells

Drug/Treatment

  • Zotiraciclib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved